All In Biotech

Drug Trial Radar · NCT06570460

Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome

Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome - A Randomized Trial

Last checked: Nov 20, 2026Latest source record: Aug 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 29, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Aarhus University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Aarhus
First posted
Aug 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This 14-month, phase IV, randomized controlled crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The study's objectives are to clarify endocrine, metabolic, cardiovascular, and thromboembolic risk factors in TS after a wash-out period without estrogen (E2) treatment; compare the effects of oral versus transdermal (TD) ERT regimens; and examine the long-term effects of E2 administration via these two routes. The study involves 50 TS women aged 18-50 years and 50 control participants. TS participants are randomized to receive either oral or TD ERT for six months, followed by crossover to the alternate treatment for another six months. Prior to randomization, any existing ERT will be discontinued for a 1-month washout period. A second 1-month washout period will occur between the two 6-month treatment phases. Laboratory analyses and clinical investigations are performed after the first wash-out period, after the first six months of treatment, and after the last six months of treatment. We anticipate that this study may provide a basis for new and improved recommendations for sex hormone replacement therapy in TS.

Conditions

  • Turner Syndrome
  • Hypogonadism; Ovarian
  • Hormone Replacement Therapy
  • Estrogen Replacement Therapy
  • Estrogen Deficiency

Interventions

  • 17-beta estradiolDrug

    Treatment with orally administered estrogen for 6 months

  • 17-beta estradiolDrug

    Treatment with transdermally administered estrogen for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blood test valuesTime frame: After 1 month of wash-out, 6 months of oral and six months of transdermal treatment
  2. Blood test valuesTime frame: After 1 month of wash-out, 6 months of oral and six months of transdermal treatment
  3. Dual energy X-ray absorptiometryTime frame: After 6 months of oral and six months of transdermal treatment
  4. Cardiovascular statusTime frame: After 6 months of oral and six months of transdermal treatment
  5. Cardiovascular statusTime frame: After 6 months of oral and six months of transdermal treatment
  6. Muscle quality (quadriceps femoris)Time frame: After 6 months of oral and six months of transdermal treatment
  7. Functional muscle testsTime frame: After 6 months of oral and six months of transdermal treatment
  8. Isometric muscle testsTime frame: After 6 months of oral and six months of transdermal treatment
  9. Maximal oxygen uptake test (VO2 max)Time frame: After 6 months of oral and six months of transdermal treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital

    Aarhus, Aarhus N, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.